Anixa Biosciences (ANIX) Fireside chat summary

Introduction and agenda

• The discussion featured the CEO of a clinical-stage biotech company focused on CAR-T cell therapy for ovarian cancer and a breast cancer vaccine, with updates on recent achievements and future plans.

• Discussion focused on recent patient survival data from a Phase 1 ovarian cancer CAR-T trial and regulatory approval for major dose escalation.

• Upcoming participation in a fireside chat to elaborate on trial observations and future plans.

Current industry trends

• CAR-T therapies for solid tumors are gaining attention due to their potential to address unmet needs in terminal cancer patients.

• Regulatory focus is shifting toward overall survival as a key endpoint for terminal cancer therapies.

• Growing confidence in intra-peritoneal CAR-T delivery as a promising approach for solid tumors.

• Introduction of lymphodepletion, a preparatory regimen, to potentially enhance CAR-T efficacy in solid tumors.

Challenges and overcoming obstacles

• Achieving capital efficiency while running two clinical trials, maintaining cash burn within $5–7 million annually since 2019, and holding a $15 million cash balance with no debt.

• Managing the risks of lymphodepletion and dose escalation in fragile patient populations.

• Patients enrolled have recurrent ovarian cancer and have failed standard therapies, representing a population with limited options.

• Absence of dose-limiting toxicities at low doses has enabled regulatory approval for significant dose escalation.